

# PROGRAM

## Sunday 25 March

15:30-	Registration/KKR Hotel Kumamoto
17:45-	Welcome reception/Kumamoto Hotel Castle

## Monday 26 March

### Main hall

7:00-8:30	<b>IONIS-sponsored satellite symposium</b> Improving Patient Outcomes in ATTR Amyloidosis Chair: Morie A. Gertz, Rochester, USA Speaker: Isabelle Lousada, Newtown, USA, Yohei Misumi, Kumamoto, Japan, Claudio Rapezzi, Bologna, Italy, Hartmut Schmidt Münster, Germany, Teresa Coelho, Porto, Portugal, Mat Maurer, New York, USA, Peter James Bonham Dyck, Rochester, USA, Márcia Waddington, Rio de Janeiro, Brazil
8:50-9:15	<b>Welcome</b> Opening remarks: Yukio Ando, Kumamoto, Japan
9:15-9:45	<b>Opening lecture</b> Chair: Yukio Ando, Kumamoto, Japan KS01, Speaker: Per Westermark, Uppsala, Sweden, Amyloid variations and nomenclature
9:45-10:15	<b>Keynote lecture</b> Diagnosis Chair: Hartmut Schmidt, Münster, Germany Chair: Bouke Hazenberg, Groningen, Netherlands 9:45-10:15, KS02, Speaker: Morie A. Gertz, Rochester, USA, Diagnosis of Amyloidosis
10:15-11:15	<b>Oral presentation</b> Diagnosis Chair: Hartmut Schmidt, Münster, Germany Chair: Bouke Hazenberg, Groningen, Netherlands 10:15-10:30, OP01, Speaker: Jennifer Kollmer, Heidelberg, Germany, In vivo monitoring of nerve lesions in symptomatic hATTR and asymptomatic gene carriers by new imaging biomarkers 10:30-10:45, OP02, Speaker: Dorota Rowczenio, London, United Kingdom, Genetic diagnosis in ATTR amyloidosis; a single UK Centre 25 year experience. 10:45-11:00, OP03, Speaker: Bouke P Hazenberg, Groningen, Netherlands, Utility of a quantitative and targeted proteomic analysis of fat tissue in systemic amyloidosis using a Selected Reaction Monitoring (SRM)-MS assay 11:00-11:15, OP04, Speaker: Cecilia Monteiro, La Jolla, USA, Development of Response to Therapy and Disease Specific Biomarkers for the Hereditary Transthyretin Amyloidoses
11:15-12:30	<b>Oral presentation</b> Basic research1 Chair: Marcus Fandrich, Ulm, Germany Chair: Marina Ramirez-Alvarado, Rochester, USA 11:15-11:30, OP13, Speaker: Wojciech Dzwolak, Warsaw, Poland, Seed-Directed Imprinting of Insulin Amyloid Fibrils: from the Obvious to the Mysterious 11:30-11:45, OP14, Speaker: M. Alejandra Tricerri, la Plata, Argentina, Amyloidosis due to natural apolipoprotein A-I Variants. Mechanisms involved in the pathogenicity pathways 11:45-12:00, OP15, Speaker: Christoph Niemiets, Münster, Germany, Interaction of TTR and SERPINA1 in ATTR Amyloidosis 12:00-12:15, OP16, Speaker: Joseph Jen-Tse Huang, Taipei, Taiwan, Photo-Controllable Probe Spatiotemporally Induces Neurotoxic Aggregates in Neurodegenerative Disease 12:15-12:30, OP17, Speaker: Gennaro Esposito, Udine, Italy, Inhibitors of Paradigmatic Amyloidogens
12:30-13:30	<b>Lunch and poster viewing</b>
13:30-14:30	<b>Poster presentation (3rd floor)</b> PA001-PA122

### 2nd hall

7:30-8:30	<b>Takeda-sponsored satellite symposium</b> Diagnosis and treatment of peripheral neuropathies Chair: Yukio Ando, Kumamoto, Japan Speaker: Haruki Koike, Nagoya, Japan
11:10-12:00	<b>Selected poster presentations</b> Chair: Jean Sipe, Boston, USA Chair: Merrill D. Benson, Indianapolis, USA PA001 Taro Yamashita, Kumamoto, Japan, Genetical and geographical features of hereditary transthyretin amyloidosis in Japan PA002 Aubin Michalon, Schlieren, Switzerland, An amyloid-selective human-derived antibody as a candidate therapeutic for ATTR amyloidosis diseases PA003 Shayna Sarosiek, Boston, USA, Serum free light chain abnormalities in systemic transthyretin amyloidosis PA056 Julius-V. Baumgart, Kiel, Germany, Amyloid of the lung and bronchi PA057 Kenji Sakai, Kanazawa, Japan, Coexistence of transthyretin- and A $\beta$ -type cerebral amyloid angiopathy in a patient with hereditary transthyretin V30M amyloidosis PA058 Kevin Alexander, Mountain View, USA, Mortality from Amyloidosis in the United States: 1979-2015
12:30-13:30	<b>ISA executive board meeting (3rd floor Tatsuda, Hanaoka)</b>
13:30-14:30	<b>Poster presentation (3rd floor)</b> PA001-PA122

## Main hall

14:30-15:00	<p><b>Keynote lecture</b> Hereditary ATTR amyloidosis 1 Chair: John Berk, Boston, USA Chair: Yoshiki Sekijima, Matsumoto, Japan 14:30-15:00, KS03, Speaker: Jeffery W. Kelly, La Jolla, USA, Towards Understanding the Etiology of the Transthyretin Amyloidoses and Ameliorating the TTR Amyloidoses</p>
15:00-16:00	<p><b>Oral presentation</b> Hereditary ATTR amyloidosis 1 Chair: John Berk, Boston, USA Chair: Yoshiki Sekijima, Matsumoto, Japan 15:00-15:15, OP05, Speaker: João Costa, Lisboa, Portugal, Clinical paradigms in treatment effectiveness for hereditary transthyretin amyloidosis 15:15-15:30, OP06, Speaker: Esther Gonzalez, Alcala de Henares, Spain, Liver transplantation for hereditary transthyretin amyloidosis (hATTR) in Spain - 25-year experience 15:30-15:45, OP07, Speaker: Bo-Göran Ericzon, Stockholm, Sweden, The 2017 year Domino Liver Transplant Register (DLTR) status on the use of Livers with Metabolic Disorders for Transplantation. Do Novel AntiAmyloidosis Drugs Have A Role in Domino Liver Transplant (DLT) Recipients? 15:45-16:00, OP08, Speaker: Luís Maia, Porto, Portugal, The cross-talk between Ocular and Central Nervous System phenotypes in ATTR V30M patients</p>
16:00-16:30	<p><b>Keynote lecture</b> Hereditary ATTR amyloidosis 2 Chair: Taro Yamashita, Kumamoto, Japan Chair: Ole Suhr, Umeå, Sweden 16:00-16:30, KS04, Speaker: Mitsuharu Ueda, Kumamoto, Japan, Early diagnosis and therapies for hereditary transthyretin amyloidosis</p>
16:30-17:50	<p><b>Symposium</b> Treatments and clinical trials Chair: Taro Yamashita, Kumamoto, Japan Chair: Ole Suhr, Umeå, Sweden 16:30-16:50, KS05, Speaker: Hartmut Schmidt, Münster, Germany, Liver Transplantation 16:50-17:10, KS06, Speaker: Laura Obici, Pavia, Italy, Tetramer stabilizers and other treatments 17:10-17:30, KS07, Speaker: Merrill D. Benson, Indianapolis, USA, Inotersen treatment for ATTR amyloidosis 17:30-17:50, KS08, Speaker: Teresa Coelho, Porto, Portugal, Patisiran, an Investigational RNAi Therapeutic for Hereditary Transthyretin-Mediated Amyloidosis: Results from the Phase 3 APOLLO study</p>
17:50-18:00	<b>Coffee break</b>
18:00-19:30	<p><b>Pfizer-sponsored satellite symposium</b> Moving the Needle in TTR-FAP: Redefining early intervention and treatment Chair: Yukio Ando, Kumamoto, Japan Chair: Márcia Waddington Cruz, Rio de Janeiro, Brazil Speaker: Márcia Waddington Cruz, Rio de Janeiro, Brazil, Real-world efficacy of Vyndaqel– what do we know? Speaker: Teresa Coelho, Porto, Portugal, Integrated Safety Analysis of Vyndaqel Speaker: Yoshiki Sekijima, Nagano, Japan, Tools to define the earliest diagnosis Speaker: Mitsuharu Ueda, Kumamoto, Japan, Redefining the patient and treatment paradigm</p>

## 2nd hall

17:50-18:00	<b>Coffee break</b>
18:00-19:00	<p><b>Janssen-sponsored satellite symposium</b> Now and Future in Diagnosis of Cardiac Amyloidosis Chair: Chihiro Shimazaki, Kyoto, Japan Speaker: Yasuhiro Izumiya, Kumamoto, Japan, Seitaro Oda, Kumamoto, Japan</p>

## Tuesday 27 March

### Main hall

7:20-8:50	<p><b>Alnylam-sponsored satellite symposium</b> Endpoints in hATTR Amyloidosis: Monitoring a Multisystemic Disease Speaker: Alejandra González-Duarte, Mexico City, Mexico, Introduction to hATTR Amyloidosis Speaker: Yesim Parman, Istanbul, Turkey, Neuropathic Manifestations of hATTR Amyloidosis and Monitoring Disease Speaker: Prof. Arnt Kristen, Heidelberg, Germany, Cardiac Manifestations of hATTR Amyloidosis and Monitoring Diseases Speaker: Dr. John L Berk, Other Clinical Measures to Assess Burden of Disease and Quality of Life</p>
8:50-9:50	<p><b>Oral presentation</b> ATTR amyloidosis 3 Chair: Ernst Hund, Heidelberg, Germany Chair: Arie Stangou, Birmingham, UK 8:50-9:05, OP18, Speaker: Violaine Plante-Bordeneuve, Créteil, France, Penetrance variation in Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) with 7 ATTR variants observed in Europe 9:05-9:20, OP19, Speaker: Masayoshi Tasaki, Pavia, Italy, Characteristics of TTR fragmentation pattern in ATTR patients carrying various mutations 9:20-9:35, OP20, Speaker: Eila Maenpaa, Boston, USA, Altered gene regulation in wild-type transthyretin (ATTRwt) amyloidosis caused by genetic risk variant, rs72922940 9:35-9:50, OP21, Speaker: Malin Olsson, Umeå, Sweden, Refine penetrance estimates in Swedish ATTR-Val30Met kindreds</p>
9:50-10:20	<p><b>Special keynote lectures</b> Chair: Teru Ogura, Kumamoto, Japan 9:50-10:20, KS09, Speaker: Keiji Tanaka, Tokyo, Japan, The Proteasome: Structure and Immunological Roles</p>
10:20-10:50	<p><b>Special keynote lectures</b> Chair: Teru Ogura, Kumamoto, Japan 10:20-10:50, KS10, Speaker: Tamotsu Yoshimori, Osaka, Japan, 21 Years of Autophagy: towards Understanding the Intracellular Self-Degradation System Fighting against Diseases and Aging</p>
10:50-11:20	<p><b>Keynote lecture</b> Pathology Chair: Per Westermark, Uppsala, Sweden Chair: Maria M. Picken, Chicago, USA 10:50-11:20, KS11, Speaker: Christoph Röcken, Kiel, Germany, The Amyloid Registry Kiel – Lessons learned from Pathology</p>
11:20-12:05	<p><b>Oral presentation</b> Pathology Chair: Per Westermark, Uppsala, Sweden Chair: Maria M. Picken, Chicago, USA 11:20-11:35, OP22, Speaker: Marcus Fändrich, Ulm, Germany, Cryo-electron microscopy structures of cross-<math>\beta</math> fibrils 11:35-11:50, OP23, Speaker: Janet A Gilbertson, London, United Kingdom, Evaluation of LDMS for diagnostic use at a Large Referral Centre 11:50-12:05, OP24, Speaker: Yohei Misumi, Kumamoto, Japan, Noninvasive screening method for ATTRm amyloidosis by using fat ultrasonography</p>
12:05-13:00	<b>Lunch and poster viewing</b>
13:00-14:00	<p><b>Poster presentation (3rd floor)</b> PB001-PB121</p>
14:00-14:30	<p><b>Keynote lecture</b> AL amyloidosis 2 Chair: Julian Gillmore, London, UK Chair: Stefan Schonland, Heidelberg, Germany 14:00-14:30, KS12, Speaker: Giampaolo Merlini, Pavia, Italy, AL amyloidosis</p>

### 2nd hall

7:30-8:40	<p><b>Selected poster presentations</b> Chair: Arie Stangou, Birmingham, UK Chair: Bo-Göran Ericzon, Stockholm, Sweden PB001 Teruaki Masuda, Kumamoto, Japan, Quantification of skin denervation in patients with transthyretin amyloid neuropathy PB002 Hirofumi Jono, Kumamoto, Japan, Effects of Cyclodextrin/Dendrimer Conjugate/shRNA Complex as a Novel Multi-target Drug on Amyloidoses PB052 Jeffrey N. Higaki, South San Francisco, USA, Detection of misfolded forms of TTR in plasma from patients with hereditary ATTR using conformation-specific TTR antibodies PB054 Richa Manwani, London UK, Targeted imaging in cardiac amyloidosis: is 18F-florbetapir the future? PB065 Lisa X. Lee, Boston, USA, Daratumumab Activity is Agnostic to Fc gamma Receptor 3A (Fc<math>\gamma</math>R3A) 158 Genotype in Patients with Refractory or Relapsed Systemic AL Amyloidosis. PB066 Yawara Kawano, Kumamoto, Japan, Analysis of clinical features of AL amyloidosis in real world: Single institute analysis of Kumamoto University Hospital PB067 Maria Gavriatopoulou, Athens, Greece, “Non-Measurable” Free Light Chains in Newly Diagnosed Patients with AL Amyloidosis: Clinical and Prognostic Implications</p>
9:50-10:50	<p><b>Oral presentation</b> AL amyloidosis 1 Chair: Chihiro Shimazaki, Kyoto, Japan Chair: Giovanni Palladini, Pavia, Italy 9:50-10:05, OP25, Speaker: Kanji Miyazaki, Tokyo, Japan, Outcomes of autologous hematopoietic cell transplantation versus chemotherapy alone in patients with light-chain amyloidosis 10:05-10:20, OP26, Speaker: Marina Ramirez-Alvarado, Rochester, United States, Differences in mutational hotspots in AL amyloidosis kappa and lambda light chains 10:20-10:35, OP27, Speaker: Moshe Gatt, Jerusalem, Israel, AL Amyloidosis is Phenotypically Different from Multiple Myeloma due to Internal Amyloidogenic Light Chain Toxicity 10:35-10:50, OP28, Speaker: Gareth J Morgan, La Jolla, United States, Small molecule stabilizers of amyloidogenic antibody light chains</p>
12:10-12:50	<b>Nomenclature meeting (3rd floor Tatsuda, Hanaoka)</b>
13:00-14:00	<p><b>Poster presentation (3rd floor)</b> PB001-PB121</p>
14:00-14:30	<p><b>Keynote lecture</b> Basic and Translational research Chair: Maria Saraiva, Porto, Portugal Chair: Kenjiro Ono, Tokyo, Japan 14:00-14:30, KS13, Speaker: Maria Saraiva, Porto, Portugal, Translation Research: Pre-clinical animal studies to exploit disease biomarkers in amyloidosis</p>

## Main hall

14:30-15:30	<p><b>Oral presentation</b> AL amyloidosis 2 Chair: Julian Gillmore, London, UK Chair: Stefan Schonland, Heidelberg, Germany 14:30-14:45, OP29, Speaker: Giovanni Palladini, Pavia, Italy, Predictors of hematologic and organ response in AL amyloidosis 14:45-15:00, OP30, Speaker: Eli Muchtar, Rochester, United States, Depth of organ response in AL amyloidosis is associated with improved survival: New proposed organ response criteria 15:00-15:15, OP31, Speaker: Hasib Sidiqi, Rochester, United States, Stem Cell Transplantation for AL Amyloidosis- Reduced mortality over time with 20 year survivors 15:15-15:30, OP32, Speaker: Efstathios Kastiris, Athens, Greece, Salvage Lenalidomide-based Therapy for Patients With AL Amyloidosis</p>
15:30-16:00	<p><b>Keynote lecture</b> AL amyloidosis 3 Chair: Arnaud Jaccard, Limoges, France Chair: Vaishali Sanchorawala, Boston, USA 15:30-16:00, KS16, Speaker: Angela Dispenzieri, Rochester, USA, Novel strategies for the treatment of AL amyloidosis</p>
16:00-17:00	<p><b>Oral presentation</b> AL amyloidosis 3 Chair: Arnaud Jaccard, Limoges, France Chair: Vaishali Sanchorawala, Boston, USA 16:00-16:15, OP37, Speaker: Christoph R Kimmich, Heidelberg, Germany, Daratumumab monotherapy in forty-eight heavily pretreated patients with advanced systemic light-chain amyloidosis 16:15-16:30, OP38, Speaker: Ute Hegenbart, Heidelberg, Germany, EGCG Treatment In Patients With Cardiac AL Amyloidosis: First Results Of A Randomized And Placebo-Controlled Clinical Trial of GERAMY 16:30-16:45, OP39, Speaker: Camille V. Edwards, Boston, United States, One Year Follow Up Analysis of the Phase 1a/b Study of Chimeric FibrilReactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis 16:45-17:00, OP40, Speaker: Xun Ma, Boston, USA, Effective Lipidoid Nanoparticle Delivery In Vitro and In Vivo of siRNA Targeting Ig Light Chain mRNA in Clonal Plasma Cells</p>
17:00-20:00	<b>Hanami tour</b>

## 2nd hall

14:30-15:10	<p><b>Symposium</b> Pathogenesis of amyloidosis Chair: Maria Saraiva, Porto, Portugal Chair: Kenjiro Ono, Tokyo, Japan 14:30-14:50, KS14, Speaker: Kenjiro Ono, Tokyo, Japan, Alzheimer's disease as oligomeropathy 14:50-15:10, KS15, Speaker: Mark Wilson, Wollongong, Australia, Clusterin and amyloid formation</p>
17:00-20:00	<b>Hanami tour</b>

## Wednesday 28 March

### Main hall

7:20-8:50	<p><b>Prothena-sponsored satellite symposium</b>            Advancing Care in Amyloidosis: Evolving Trends and Future Directions            Chair: Giampaolo Merlini, Pavia, Italy            Chair: Morie A. Gertz, Rochester, USA            Speaker: Pablo Garcia-Pavia, Madrid, Spain, Cardiac amyloidosis: can we diagnose it earlier?            Speaker: Martha Grogan, Rochester, USA, Role of imaging in amyloidosis: past, present and future            Speaker: Giovanni Palladini, Pavia, Italy, What does minimal residual disease mean in AL amyloidosis?</p>
8:50-9:20	<p><b>Keynote lecture</b>            Basic research and animal models            Chair: Joel Buxbaum, La Jolla, USA            Chair: Keiichi Higuchi, Matsumoto, Japan            8:50-9:20, KS17, Speaker: Gunilla Westermark, Uppsala, Sweden, What can we learn from animal?</p>
9:20-10:20	<p><b>Oral presentation</b>            Basic research and animal models            Chair: Joel Buxbaum, La Jolla, USA            Chair: Keiichi Higuchi, Matsumoto, Japan            9:20-9:35, OP33, Speaker: Rita Del Giudice, Lund, Sweden, Organ-specificity of Apolipoprotein A-I amyloidogenic variants: the role of the extracellular environment            9:35-9:50, OP34, Speaker: Lorena Saelices, Los Angeles, United States, Amyloid seeding of transthyretin caused by ATTR cardiac fibrils and its inhibition            9:50-10:05, OP35, Speaker: Sung-Tsang Hsieh, Taipei, Taiwan, "Degeneration of sensory nerves in a Knock-in Mouse Model of Transthyretin(Ala97Ser) Amyloid Neuropathy"            10:05-10:20, OP36, Speaker: Jennifer Ward, Boston, United States, Modeling amyloidogenic LC proteotoxicity in zebrafish</p>
10:20-10:50	<p><b>Keynote lecture</b>            Wild-type ATTR amyloidosis            Chair: Martha Grogan, Rochester, USA            Chair: Thibaud Damy, Paris, France            10:20-10:50, KS18, Speaker: Per Westermark, Uppsala, Sweden, Wild-type ATTR amyloidosis – an introduction to a prevalent systemic disease</p>
10:50-12:05	<p><b>Oral presentation</b>            Wild-type ATTR amyloidosis            Chair: Martha Grogan, Rochester, USA            Chair: Thibaud Damy, Paris, France            10:50-11:05, OP41, Speaker: Sami L. Khella, Philadelphia, United States, Prevalence and severity of peripheral and autonomic neuropathy in THAOS subjects with wild-type or hereditary transthyretin cardiac amyloidosis            11:05-11:20, OP43, Speaker: Per A Eldhagen, Stockholm, Sweden, Is lumbar spinal stenosis an early sign of systemic ATTR amyloidosis?            11:20-11:35, OP42, Speaker: Celia Torres-Arancivia, Boston, USA, Effect of TTR tetramer stabilizing agents on clusterin levels in ATTRwt amyloidosis            11:35-11:50, OP44, Speaker: Celia Torres-Arancivia, Boston, United States, Structural studies on ATTRwt serum clusterin            11:50-12:05, OP66, Speaker: Joel N. Buxbaum, La Jolla, USA, Transthyretin inhibition of amyloidogenesis in vitro and in vivo: protein-protein interactions across biologic kingdom</p>
12:05-13:00	<p><b>Lunch and poster viewing</b></p>
13:00-14:00	<p><b>Poster presentation (3rd floor)</b>            PC001-PC120</p>

### 2nd hall

7:30-8:30	<p><b>Selected poster presentations</b>            Chair: Robert Kisilevsky, Ontario, Canada            Chair: Raymond Comenzo, Boston, USA            PC001 Kengo Korai, Osaka, Japan, Regional variation of amyloid deposition in an autopsy heart of a senile systemic amyloidosis case with long-term clinical course            PC002 Carolina Lemos, Porto, Portugal, The role of genetic factors of Alzheimer and Parkinson disease as modulators of age-at-onset on Familial Amyloid Polyneuropathy            PC060 Tsuneaki Yoshinaga, Matsumoto, Japan, The first case of wild-type cystatin C amyloidosis identified from granulomatous amyloidoma in the rectum            PC065 Mohamed Samir El-Sady, Boston, USA, Relation between myocardial amyloid burden by 18F-florbetapir PET and severity of heart failure in light chain amyloidosis            PC066 Marco Basset, Pavia Italy, Treatment with pomalidomide and dexamethasone in patients with light chain AL amyloidosis and multiple myeloma            PC067 Yukihiko Otaka, Takasaki, Japan, Systemic heavy and light chain amyloidosis presenting nephrotic syndrome and congestive heart failure: A case presentation and literature review</p>
12:15-12:45	<p><b>The Amyloid editors meeting (3rd floor Tatsuda, Hanaoka)</b></p>
13:00-14:00	<p><b>Poster presentation (3rd floor)</b>            PC001-PC120</p>

## Main hall

14:00-14:30	<p><b>Keynote lecture</b> Cardiac amyloidosis Chair: Claudio Rapezzi, Bologna, Italy Chair: Arnt V Kristen, Heidelberg, Germany 14:00-14:30, KS19, Speaker: Mathew Maurer, New York, USA, Cardiac Amyloidosis</p>
14:30-15:30	<p><b>Oral presentation</b> Cardiac amyloidosis Chair: Claudio Rapezzi, Bologna, Italy Chair: Arnt V Kristen, Heidelberg, Germany 14:30-14:45, OP45, Speaker: Thibaud Damy, Creteil, France, Cardiac amyloidosis in Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey 14:45-15:00, OP46, Speaker: Ashutosh Wechalekar, London, United Kingdom, 99mTc-DPD Scintigraphy Is An Independent Predictor Of Outcomes In Cardiac AL Amyloidosis 15:00-15:15, OP47, Speaker: Julian Gillmore, London, United Kingdom, Transthyretin amyloidosis cardiomyopathy: Genotype, phenotype, natural history and quality of life in 1034 patients seen at the UK national referral centre in the UK 15:15-15:30, OP48, Speaker: Tobias Dittrich, Heidelberg, Germany, AL amyloidosis cardiac staging systems retain their important prognostic value also in patients with impaired renal function and atrial fibrillation</p>
15:30-16:00	<p><b>Keynote lecture</b> Proteinopathies and other types of amyloidosis Chair: Hironobu Naiki, Fukui, Japan Chair: Masahide Yazaki, Matsumoto, Japan 15:30-16:00, KS20, Speaker: Masato Hasegawa, Tokyo, Japan, Transmission of <math>\alpha</math>-synuclein</p>
16:00-17:00	<p><b>Oral presentation</b> Proteinopathies and other types of amyloidosis Chair: Hironobu Naiki, Fukui, Japan Chair: Masahide Yazaki, Matsumoto, Japan 16:00-16:15, OP53, Speaker: Joakim Bergstrom, Uppsala, Sweden, Aggregated alpha-synuclein is spread via tunnelling nanotubes in cultured human astrocytes 16:15-16:30, OP54, Speaker: Per Hammarström, Linköping, Sweden, Amyloid polymorphism and cell specific toxicity in vivo 16:30-16:45, OP55, Speaker: Matteo de Rosa, Milano, Italy, Structural bases of gelsolin amyloidosis 16:45-17:00, OP56, Speaker: Teerin Liewluck, Rochester, United States, Isolated Amyloid Myopathy: An Emerging Group of Hereditary Localized Amyloidosis</p>
18:30-	<b>Banquet/ANA crowne plaza Kumamoto new sky hotel</b>

## 2nd hall

14:00-15:00	<p><b>Oral presentation</b> Basic Research 2 Chair: Janne Johansson, Stockholm, Sweden Chair: Hirofumi Kai, Kumamoto, Japan 14:00-14:15, OP49, Speaker: Jan Gettemans, Ghent, Belgium, Serum Amyloid P component nanobodies, a new tool in amyloid research 14:15-14:30, OP50, Speaker: Diana Santos, Porto, Portugal, Larger normal repeats of ATXN2 gene may decrease age-at-onset in Portuguese familial amyloid polyneuropathy (TTR-FAP Val30Met) patients 14:30-14:45, OP51, Speaker: Aleksandar Jeremic, Washington, United States, Proteasome regulates turnover of toxic human islet amyloid polypeptide 14:45-15:00, OP52, Speaker: Miguel Alves-Ferreira, Porto, Portugal, Variants in the transthyretin gene region as modulators of disease expressivity</p>
15:00-16:15	<p><b>Oral presentation</b> Epidemiology Chair: Reinhold Linke, München, Germany Chair: Violaine Plante-Bordeneuve, Créteil, France 15:00-15:15, OP57, Speaker: Peter Mollee, Brisbane, Australia, The Epidemiology of Amyloidosis in Australia 15:15-15:30, OP58, Speaker: Márcia Waddington Cruz, Rio de Janeiro, Brazil, Geographic distribution of ATTR cases from CEPARM (Centro de Estudos em Paramiloidose Antônio Rodrigues de Mello) across the Brazilian territory and their clinical aspects, demographics, ethnical and family background. 15:30-15:45, OP59, Speaker: Alejandra Gonzalez-Duarte, Mexico City, Mexico, A descriptive analysis of subjects with the Ser50Arg mutation enrolled in the Transthyretin Amyloidosis Outcomes Survey 15:45-16:00, OP60, Speaker: Toshiyuki Yamada, Tochigi, Japan, Features and changes in AA amyloidosis in Japan 16:00-16:15, OP61, Speaker: Renato Polimanti, New Haven, United States, Increased risk of multiple outpatient surgery in carriers of TTR V122I mutation in a relatively young cohort of 4,361 African-Americans</p>
18:30-	<b>Banquet/ANA crowne plaza Kumamoto new sky hotel</b>

## Thursday 29 March

### Main hall

7:40-8:40	<b>Eidos-sponsored satellite symposium</b>
8:50-9:20	<b>Keynote lecture</b> AA amyloidosis Chair: Toshiyuki Yamada, Tochigi, Japan Chair: Barbara Kluge-Beckerman, Indianapolis, USA 8:50-9:20, KS21, Speaker: Olga Gursky, Boston, USA, Structure-based function of serum amyloid A and its oligomerization at lysosomal pH
9:20-10:20	<b>Oral presentation</b> AA amyloidosis Chair: Toshiyuki Yamada, Tochigi, Japan Chair: Barbara Kluge-Beckerman, Indianapolis, USA 9:20-9:35, OP09, Speaker: Masafumi Tanaka, Kobe, Japan, Effect of Carboxyl-Terminal Truncation on Amyloid Fibril Formation of Human Serum Amyloid A 9:35-9:50, OP10, Speaker: Cornelia Loos, Ulm, Germany, Systemically conserved pathways of protein misfolding in vivo 9:50-10:05, OP11, Speaker: Ioana Puscalau-Girtu, Ulm, Germany, Cellular mechanism of fibril formation from serum amyloid A1 protein 10:05-10:20, OP12, Speaker: Sophie Georjin-Lavialle, Paris, France, Obesity as a cause of AA amyloidosis: a case series of 15 patients
10:20-10:50	<b>Keynote lecture</b> CAA and other brain amyloidosis Chair: Masahito Yamada, Kanazawa, Japan Chair: Roxana O Carare, Southampton, UK 10:20-10:50, KS25, Speaker: Roxana O Carare, Southampton, UK, Intramural Periarterial Drainage Pathways and the pathogenesis of neurological diseases
10:50-11:50	<b>Oral presentation</b> CAA and other brain amyloidosis Chair: Masahito Yamada, Kanazawa, Japan Chair: Roxana O Carare, Southampton, UK 10:50-11:05, OP62, Speaker: Yasuteru Inoue, Kumamoto-City, Japan, Sushi repeat-containing protein 1 co-accumulates with cerebrovascular A $\beta$ deposits in cerebral amyloid angiopathy 11:05-11:20, OP63, Speaker: Masaya Ikegawa, Kyoto, Japan, Visualization of Amyloid beta deposits in human brain with MALDI Imaging Mass Spectrometry 11:20-11:35, OP64, Speaker: Jan Johansson, Huddinge, Sweden, Bri2 BRICHOS is a multifunctional chaperone with activity against amyloid formation as well as non-fibrillar aggregation 11:35-11:50, OP65, Speaker: Pavel Semenyuk, Moscow, Russia, Amyloid aggregation of alpha-synuclein and prion protein can be controlled using polyanions
12:00-13:00	<b>Lunch and poster viewing</b>
13:00-13:20	<b>Taylor &amp; Francis (from the managing editor of Amyloid)</b> Chair: Per Westermark, Uppsala, Sweden
13:20-13:40	<b>ISA members meeting</b> Chair: Angela Dispenzneri, Rochester, USA
13:40-13:55	<b>Summary of the Symposium</b> Ole Suhr, Umeå, Sweden
13:55-	<b>The next symposium/Next symposium Spain</b>
14:00-	<b>Closing remarks</b>

### 2nd hall

8:50-9:50	<b>Symposium</b> ATTRm amyloidosis guidelines Chair: Taro Yamashita, Kumamoto, Japan Chair: Márcia Waddington Cruz, Rio De Janeiro, Brazil 8:50-9:10, KS22, Speaker: Laura Obici, Pavia, Italy, European consensus of diagnosis and treatments for ATTRm amyloidosis 9:10-9:30, KS23, Speaker: Isabel Conceição, Lisbon, Portugal, ATTRm amyloidosis diagnosis guidelines 9:30-9:50, KS24, Speaker: Yoshiki Sekijima, Matsumoto, Japan, Japanese consensus of diagnosis and treatments for ATTRm amyloidosis